codeunknown
Posts: 22615
Alba Posts: 9
Joined: 7/14/2004
Member: #704
|
Here's a small compilation of evidence I put together against dietary saturated fat and serum LDL cholesterol as mediators of heart disease. With caveats about stroke and distinctions between the variety of fats. For you, Blue, to attain a slightly better understanding of those "dumb" studies.
Feel free to survey the body of evidence or pick and choose select studies.
---
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106:3143.
Broedl, UC, Geiss, HC, Parhofer, KG. Comparison of current guidelines for primary prevention of coronary heart disease. J Gen Intern Med 2003; 18:190.
Wallis, EJ, Ramsay, LE, Ul Haq, I, et al. Coronary and cardiovascular risk estimation for primary prevention: Validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320:671.
Pekkanen, J, Linn, S, Hetgg, G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700.
Gould, AL, Rossouw, JE, Santanello, NC, et al. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 1998; 97:946.
Ballantyne, CM, Grundy, SM, Oberman, A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000; 85:2089.
D'Agostino RB, Sr, Grundy, S, Sullivan, LM, Wilson, P. Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation. JAMA 2001; 286:180.
Bastuji-Garin, S, Deverly, A, Moyse, D, Castaigne, A. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973.
Brindle, P, Emberson, J, Lampe, F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327:1267.
Liu, J, Hong, Y, D'Agostino RB, Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291:2591.
Fedder, DO, Koro, CE, L'Italien, GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002; 105:152.
Kinosian, B, Glick, H, Garland, G. Cholesterol and coronary heart disease: Predicting risks by levels and ratios. Ann Intern Med 1994; 121:641.
Steyn, K, Sliwa, K, Hawken, S, et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 2005; 112:3554.
Otvos, JD, Collins, D, Freedman, DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113:1556.
Cui, Y, Blumenthal, RS, Flaws, JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161:1413.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.
Sacks, FM, Pfeffer, MA, Moye, LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.
Shepherd, J, Cobbe, SM, Ford, I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301.
Sever, PS, Dahlof, B, Poulter, NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149.
Downs, JR, Clearfield, M, Weis, S, et al for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615.
Kumana, CR, Cheung, BM, Lauder, IJ. Gauging the impact of statins using number needed to treat. JAMA 1999; 282:1899.
Marchioli, R, Marfisi, RM, Carcini, F, Tognoni, G. Meta-analysis, clinical trials, and transferability of research results into practice: The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 1996; 156:1158.
Wilt, TJ, Bloomfield, HE, MacDonald, R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164:1427.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.
Brown, BG, Zhao, XQ, Sacco, DE, Albers, JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87:1781. Pedersen, TR, Kjekshus, J, Berg, K, et al. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93:1796.
Kane, JP, Malloy, MJ, Ports, TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007.
Grundy, SM, Balady, GJ, Criqui, MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997; 95:1683.
Grundy, SM, Cleeman, JI, Merz, CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227. Cannon, CP, Braunwald, E, McCabe, CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.
de Lemos, JA. Blazing, MA, Wiviott, SD, et al. Early Intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 2004; 292:1307.
Grover, SA, Coupal, L, Hu, XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274:801.
Ramsay, LE, Haq, IU, Yeo, WW, et al. Targeted lipid lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table. Lancet 1996; 348:387.
Anderson, KM, Odell, PM, Wilson, PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293.
Johannesson, M, Jonsson, B, Kjiekshus, J, et al for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336:332.
Tsevat, J, Kuntz, KM, Orav, EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141:727.
Perreault, S, Hamilton, VH, Lavoie, F, et al. Treating hyperlipidemia for the primary prevention of coronary disease: Are higher doses of lovastatin cost-effective? Arch Intern Med 1998; 157:375.
Manninen, V, Tenkanen, L, Koskinen, P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992; 85:37.
Law, MR, Thompson, SG, Wald, NJ. Assessing possible hazards of reducing serum cholesterol. Br Med J 1994; 308:373.
Hebert, PR, Gaziano, JM, Chan, KS, Hennekens, CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313.
Muldoon, MF, Manuck, SB, Mendelsohn, AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001; 322:11.
Golomb, BA, Kane, T, Dimsdale, JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004; 97:229.
Lloyd-Jones, DM, O'Donnell, CJ, D'Agostino, RB, et al. Applicability of cholesterol-lowering primary prevention trials to a general population: The Framingham Heart Study. Arch Intern Med 2001; 161:949. Cashin-Hemphill, L, Mack, WJ, Pogoda, JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264:3013.
Brown, G, Albers, JJ, Fisher, LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289.
Andrade, SE, Walerks, AM, Gottlieb, LK, et al. Discontinuation of antihyperlipidemic drugs — Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332:1125.
Pedersen, TR, Berg, K, Cook, TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156:2085.
Sacks, FM, Tonkin, AM, Craven, T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105:1424.
Collins, R, Armitage, J, Parish, S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005.
Colhoun, HM, Betteridge, DJ, Durrington, PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685.
Kearney, PM, Blackwell, L, Collins, R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.
Shepherd, J, Blauw, GJ, Murphy, MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623.
Kaiser, FE. Cholesterol and the older adult. South Med J 1993; 86:2511.
Rosenson, RS. Beyond low-density lipoprotein cholesterol: A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 1996; 156:1278.
Harper, CR, Jacobson, TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999; 159:1049.
Butowski, PF, Winder, AF. Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolemia: Data from the UK Lipid Clinics Programme. Eur Heart J 1998; 19:1328.
Jenkins, DJ, Kendall, CW, Marchie, A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502.
Stefanick, ML, Mackey, S, Sheehan, M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998; 339:12.
Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.
Byington, RP, Jukema, JW, Salonen, JT, et al. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92:2419.
Denke, MA, Adams-Huet, B, Nguyen, AT. Individual cholesterol variation in response to a margarine- or butter-based diet: A study in families. JAMA 2000; 284:2740.
Henkin, Y, Shai, I, Zuk, R, et al. Dietary treatment of hypercholesterolemia: Do dietitians do it better? A randomized, controlled trial. Am J Med 2000; 109:549.
Hsia, J, Rodabough, R, Rosal, MC, et al. Compliance with National Cholesterol Education Program dietary and lifestyle guidelines among older women with self-reported hypercholesterolemia. The Women's Health Initiative. Am J Med 2002; 113:384.
Canner, PL, Berge, KG, Wenger, NK. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245.
Keech, A, Simes, RJ, Barter, P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.
Rubins, HB, Robins, SJ, Collins, D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410.
Larsen, ML, Illingworth, DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994; 78:225. Levy, RI, Troendle, AJ, Fattu, JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87:III45.
Illingworth, DR, Stein, EA, Mitchel, YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154:1586.
Sprecher, DL, Abrams, J, Allen, JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120:537.
Jones, P, Kafonek, S, Laurora, I, et al for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582.
Bakker-Arkema, RG, Davidson, MH, Goldstein, RJ, et al. Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 276:128.
Davidson, M, McKenney, J, Stein, E, et al., for the Atorvastatin Study Group I. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79:1475.
Jones, PH, Davidson, MH, Stein, EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152.
Jula, A, Marniemi, J, Huupponen, R, et al. Effects of Diet and Simvastatin on Serum Lipids, Insulin, and Antioxidants in Hypercholesterolemic Men: A Randomized Controlled Trial. JAMA 2002; 287:598. Fruchart, JC, Brewer, HB, Leitersdorf, E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998; 81:912.
Staels, B, Dallongeville, J, Auwerx, J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088.
Grundy, SM, Mok, HY, Zech, L, Berman, M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981; 22:24.
Probstfield, JL, Hunninghake, DB. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med 1994; 154:1557.
Pearson, TA, Laurora, I, Chu, H, Kafonek, S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid- lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459.
Glasziou, PP, Irwig, L, Heritier, S, et al. Monitoring cholesterol levels: measurement error or true change?. Ann Intern Med 2008; 148:656.
Posner, B, Cobb, JL, Belanger, A, et al. Dietary lipid predictors of coronary heart disease in men. Arch Intern Med 1991; 151:1181.
Hegsted, DM, Ausman, LM, Johnson, JA, Dallal, GE. Dietary fat and serum lipids: An evaluation of the experimental data. Am J Clin Nutr 1993; 57:875.
Meyer, KA, Kushi, LH, Jacobs, DR Jr, Folsom, AR. Dietary fat and incidence of type 2 diabetes in older Iowa women. Diabetes Care 2001; 24:1528.
Fuentes, F, Lopez-Miranda, J, Sanchez, E, et al. Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic patients. Ann Intern Med 2001; 134:1115.
Mensink, RP, Katan, MB. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men. N Engl J Med 1989; 321:436.
Mata, P, Alavrez-Sala, LA, Rubio, MJ, et al. Effects of long-term monounsaturated- vs polyunsaturated-enriched diets on lipoproteins in healthy men and women. Am J Clin Nutr 1992; 55:846.
Ascherio, A, Rimm, EB, Giovannucci, EL, et al. Dietary fat and risk of coronary heart disease in men: Cohort follow up study in the United States. BMJ 1996; 313:84.
Lichtenstein, AH, Ausman, LM, Jalbert, SM, Schaefer, EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 1999; 340:1933.
Ascherio, A, Hennekens, CH, Buring, JE, et al. Trans-fatty acid intake and risk of myocardial infarction. Circulation 1994; 89:94.
Hooper, L, Summerbell, CD, Higgins, JP, et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 2001; 322:757.
Sh-t in the popcorn to go with sh-t on the court. Its a theme show like Medieval times.
|